A nurse is caring for a client who is experiencing adverse effects after receiving a new medication

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

Try the new Google Books

Check out the new look and enjoy easier access to your favorite features

1. Goff DC. Maintenance treatment with long‐acting injectable antipsychotics: comparing old with new. JAMA 2014;311:1973‐4. [PubMed] [Google Scholar]

2. International College of Neuropsychopharmacology . CINP schizophrenia guidelines. //cinp.org/cinp-schizophrenia-guidelines/.

3. Schimmelmann BG, Schmidt SJ, Carbon M et al. Treatment of adolescents with early‐onset schizophrenia spectrum disorders: in search of a rational, evidence‐informed approach. Curr Opin Psychiatry 2013;26:219‐30. [PubMed] [Google Scholar]

4. Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence‐based practice. J Clin Psychiatry 2013;74:1108‐20. [PubMed] [Google Scholar]

5. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947‐56. [PMC free article] [PubMed] [Google Scholar]

6. Brar JS, Ganguli R, Pandina G et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:205‐12. [PubMed] [Google Scholar]

7. Seemuller F, Lewitzka U, Bauer M. The relationship of akathisia with treatment emergent suicidality among patients with first‐episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012;45:292‐6. [PubMed] [Google Scholar]

8. Tarsy D. Neuroleptic‐induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983;6(Suppl. 1):S9‐26. [PubMed] [Google Scholar]

9. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623‐6. [PMC free article] [PubMed] [Google Scholar]

10. Keepers GA, Casey DE. Use of neuroleptic‐induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991;148:85‐9. [PubMed] [Google Scholar]

11. Aguilar EJ, Keshavan MS, Martinez‐Quiles MD et al. Predictors of acute dystonia in first‐episode psychotic patients. Am J Psychiatry 1994;151:1819‐21. [PubMed] [Google Scholar]

12. Swett C Jr. Drug‐induced dystonia. Am J Psychiatry 1975;132:532‐4. [PubMed] [Google Scholar]

13. Koek RJ, Pi EH. Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 1989;30:359‐64. [PubMed] [Google Scholar]

14. Gardner DM, Abidi S, Ursuliak Z et al. Incidence of oculogyric crisis and long‐term outcomes with second‐generation antipsychotics in a first‐episode psychosis program. J Clin Psychopharmacol 2015;35:715‐8. [PubMed] [Google Scholar]

15. Arana GW, Goff DC, Baldessarini RJ et al. Efficacy of anticholinergic prophylaxis for neuroleptic‐induced acute dystonia. Am J Psychiatry 1988;145:993‐6. [PubMed] [Google Scholar]

16. Goff DC, Arana GW, Greenblatt DJ et al. The effect of benztropine on haloperidol‐induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double‐blind trial. J Clin Psychopharmacol 1991;11:106‐12. [PubMed] [Google Scholar]

17. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979;61:261‐2. [PubMed] [Google Scholar]

18. Winslow RS, Stillner V, Coons DJ et al. Prevention of acute dystonic reactions in patients beginning high‐potency neuroleptics. Am J Psychiatry 1986;143:706‐10. [PubMed] [Google Scholar]

19. Swett C Jr, Cole JO, Shapiro S et al. Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis. Arch Gen Psychiatry 1977;34:942‐3. [PubMed] [Google Scholar]

20. Desmarais JE, Beauclair L, Annable L et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol 2014;4:257‐67. [PMC free article] [PubMed] [Google Scholar]

21. Caradoc‐Davies G, Menkes DB, Clarkson HO et al. A study of the need for anticholinergic medication in patients treated with long‐term antipsychotics. Aust N Z J Psychiatry 1986;20:225‐32. [PubMed] [Google Scholar]

22. Chan HY, Chang CJ, Chiang SC et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced acute dystonia or parkinsonism. J Psychopharmacol 2010;24:91‐8. [PMC free article] [PubMed] [Google Scholar]

23. Altamura AC, Mauri MC, Mantero M et al. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 1987;76:702‐6. [PubMed] [Google Scholar]

24. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic‐induced acute dystonia and akathisia. Am J Psychiatry 1978;135:1232‐3. [PubMed] [Google Scholar]

25. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009;85:322‐6. [PubMed] [Google Scholar]

26. Caligiuri MP, Lohr JB. Instrumental motor predictors of neuroleptic‐induced parkinsonism in newly medicated schizophrenia patients. J Neuropsychiatry Clin Neurosci 1997;9:562‐7. [PubMed] [Google Scholar]

27. Hriso E, Kuhn T, Masdeu JC et al. Extrapyramidal symptoms due to dopamine‐blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991;148:1558‐61. [PubMed] [Google Scholar]

28. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism. Mov Disord 1999;14:128‐31. [PubMed] [Google Scholar]

29. Chang A, Fox SH. Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management. Drugs 2016;76:1093‐18. [PubMed] [Google Scholar]

30. Samudra N, Patel N, Womack KB et al. Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging 2016;33:855‐63. [PMC free article] [PubMed] [Google Scholar]

31. Taylor J, Anderson WS, Brandt J et al. Neuropsychiatric complications of Parkinson disease treatments: importance of multidisciplinary care. Am J Geriatr Psychiatry 2016;24:1171‐80. [PMC free article] [PubMed] [Google Scholar]

32. Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic‐induced parkinsonism. Drug Saf 1999;20:269‐75. [PubMed] [Google Scholar]

33. Cortese L, Caligiuri MP, Williams R et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28:69‐73. [PubMed] [Google Scholar]

34. Magnus RV. A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug‐induced Parkinsonism. J Int Med Res 1980;8:343‐6. [PubMed] [Google Scholar]

35. Dayalu P, Chou KL. Antipsychotic‐induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008;9:1451‐62. [PubMed] [Google Scholar]

36. Ananth J, Sangani H, Noonan JP. Amantadine in drug‐induced extrapyramidal signs: a comparative study. Int J Clin Pharmacol Biopharm 1975;11:323‐6. [PubMed] [Google Scholar]

37. Chouinard G, Annable L, Ross‐Chouinard A et al. Ethopropazine and benztropine in neuroleptic‐induced parkinsonism. J Clin Psychiatry 1979;40:147‐52. [PubMed] [Google Scholar]

38. Kelly JT, Zimmermann RL, Abuzzahab FS et al. A double‐blind study of amantadine hydrochloride versus benztropine mesylate in drug‐induced parkinsonism. Pharmacology 1974;12:65‐73. [PubMed] [Google Scholar]

39. Mindham RH, Gaind R, Anstee BH et al. Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine‐induced Parkinsonism. Psychol Med 1972;2:406‐13. [PubMed] [Google Scholar]

40. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167‐70. [PubMed] [Google Scholar]

41. Van Putten T. Vulnerability to extrapyramidal side effects. Clin Neuropharmacol 1983;6(Suppl. 1):S27‐34. [PubMed] [Google Scholar]

42. Miller CH, Hummer M, Oberbauer H et al. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 1997;7:51‐5. [PubMed] [Google Scholar]

43. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug‐induced akathisia. Arch Gen Psychiatry 1994;51:963‐74. [PubMed] [Google Scholar]

44. Juncal‐Ruiz M, Ramirez‐Bonilla M, Gomez‐Arnau J et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non‐affective psychosis: a 6‐week randomised study of antipsychotic treatment. Psychopharmacology 2017;234:2563‐70. [PubMed] [Google Scholar]

45. Poyurovsky M. Acute antipsychotic‐induced akathisia revisited. Br J Psychiatry 2010;196:89‐91. [PubMed] [Google Scholar]

46. Poyurovsky M, Pashinian A, Weizman R et al. Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biol Psychiatry 2006;59:1071‐7. [PubMed] [Google Scholar]

47. Adler L, Angrist B, Peselow E et al. A controlled assessment of propranolol in the treatment of neuroleptic‐induced akathisia. Br J Psychiatry 1986;149:42‐5. [PubMed] [Google Scholar]

48. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic‐induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989;11:107‐19. [PubMed] [Google Scholar]

49. Kramer MS, Gorkin RA, DiJohnson C et al. Propranolol in the treatment of neuroleptic‐induced akathisia (NIA) in schizophrenics: a double‐blind, placebo‐controlled study. Biol Psychiatry 1988;24:823‐7. [PubMed] [Google Scholar]

50. Lima AR, Bacalcthuk J, Barnes TR et al. Central action beta‐blockers versus placebo for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2004;4:CD001946. [PMC free article] [PubMed] [Google Scholar]

51. Rathbone J, Soares‐Weiser K. Anticholinergics for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2006;4:CD003727. [PMC free article] [PubMed] [Google Scholar]

52. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic‐induced akathisia. J Clin Psychopharmacol 1990;10:12‐21. [PubMed] [Google Scholar]

53. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic‐induced akathisia. Ann Pharmacother 2008;42:841‐6. [PubMed] [Google Scholar]

54. Praharaj SK, Kongasseri S, Behere RV et al. Mirtazapine for antipsychotic‐induced acute akathisia: a systematic review and meta‐analysis of randomized placebo‐controlled trials. Ther Adv Psychopharmacol 2015;5:307‐13. [PMC free article] [PubMed] [Google Scholar]

55. Miller CH, Fleischhacker WW, Ehrmann H et al. Treatment of neuroleptic induced akathisia with the 5‐HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373‐6. [PubMed] [Google Scholar]

56. Miller CH, Hummer M, Pycha R et al. The effect of ritanserin on treatment‐resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:247‐51. [PubMed] [Google Scholar]

57. Poyurovsky M, Fuchs C, Weizman A. Low‐dose mianserin in treatment of acute neuroleptic‐induced akathisia. J Clin Psychopharmacol 1998;18:253‐4. [PubMed] [Google Scholar]

58. Poyurovsky M, Shardorodsky M, Fuchs C et al. Treatment of neuroleptic‐induced akathisia with the 5‐HT2 antagonist mianserin. Double‐blind, placebo‐controlled study. Br J Psychiatry 1999;174:238‐42. [PubMed] [Google Scholar]

59. Avital A, Gross‐Isseroff R, Stryjer R et al. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic‐induced akathisia: a comparative double‐blind study. Eur Neuropsychopharmacol 2009;19:476‐82. [PubMed] [Google Scholar]

60. Fischel T, Hermesh H, Aizenberg D et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic‐induced akathisia: a comparative double‐blind study. J Clin Psychopharmacol 2001;21:612‐5. [PubMed] [Google Scholar]

61. Hirose S, Ashby CR. Immediate effect of intravenous diazepam in neuroleptic‐induced acute akathisia: an open‐label study. J Clin Psychiatry 2002;63:524‐7. [PubMed] [Google Scholar]

62. Bartels M, Heide K, Mann K et al. Treatment of akathisia with lorazepam. An open clinical trial. Pharmacopsychiatry 1987;20:51‐3. [PubMed] [Google Scholar]

63. Kutcher S, Williamson P, MacKenzie S et al. Successful clonazepam treatment of neuroleptic‐induced akathisia in older adolescents and young adults: a double‐blind, placebo‐controlled study. J Clin Psychopharmacol 1989;9:403‐6. [PubMed] [Google Scholar]

64. Pujalte D, Bottai T, Hue B et al. A double‐blind comparison of clonazepam and placebo in the treatment of neuroleptic‐induced akathisia. Clin Neuropharmacol 1994;17:236‐42. [PubMed] [Google Scholar]

65. Lima AR, Soares‐Weiser K, Bacaltchuk J et al. Benzodiazepines for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2002;1:CD001950. [PMC free article] [PubMed] [Google Scholar]

66. Tiihonen J, Mittendorfer‐Rutz E, Torniainen M et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow‐up study. Am J Psychiatry 2016;173:600‐6. [PubMed] [Google Scholar]

67. Lerner V, Bergman J, Statsenko N et al. Vitamin B6 treatment in acute neuroleptic‐induced akathisia: a randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry 2004;65:1550‐4. [PubMed] [Google Scholar]

68. Bernstein AL. Vitamin B6 in clinical neurology. Ann N Y Acad Sci 1990;585:250‐60. [PubMed] [Google Scholar]

69. Erdur B, Tura P, Aydin B et al. A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide‐induced akathisia. Am J Emerg Med 2012;30:84‐91. [PubMed] [Google Scholar]

70. Friedman BW, Bender B, Davitt M et al. A randomized trial of diphenhydramine as prophylaxis against metoclopramide‐induced akathisia in nauseated emergency department patients. Ann Emerg Med 2009;53:379‐85. [PubMed] [Google Scholar]

71. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26:265‐70. [PubMed] [Google Scholar]

72. Cornett EM, Novitch M, Kaye AD et al. Medication‐induced tardive dyskinesia: a review and update. Ochsner J 2017;17:162‐74. [PMC free article] [PubMed] [Google Scholar]

73. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87:132‐41. [PubMed] [Google Scholar]

74. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701‐15. [PubMed] [Google Scholar]

75. Tenback DE, van Harten PN, Slooff CJ et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163:1438‐40. [PubMed] [Google Scholar]

76. Tenback DE, van Harten PN, van Os J. Non‐therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta‐analysis. Mov Disord 2009;24:2309‐15. [PubMed] [Google Scholar]

77. Miller DD, McEvoy JP, Davis SM et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33‐43. [PubMed] [Google Scholar]

78. Zhang XY, Chen DC, Qi LY et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology 2009;205:647‐54. [PubMed] [Google Scholar]

79. Bakker PR, van Harten PN, van Os J. Antipsychotic‐induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta‐analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544‐56. [PubMed] [Google Scholar]

80. Zai CC, Tiwari AK, Muller DJ et al. The catechol‐O‐methyl‐transferase gene in tardive dyskinesia. World J Biol Psychiatry 2010;11:803‐12. [PubMed] [Google Scholar]

81. Miura I, Zhang JP, Nitta M et al. BDNF Val66Met polymorphism and antipsychotic‐induced tardive dyskinesia occurrence and severity: a meta‐analysis. Schizophr Res 2014;152:365‐72. [PMC free article] [PubMed] [Google Scholar]

82. Inada T, Koga M, Ishiguro H et al. Pathway‐based association analysis of genome‐wide screening data suggest that genes associated with the gamma‐aminobutyric acid receptor signaling pathway are involved in neuroleptic‐induced, treatment‐resistant tardive dyskinesia. Pharmacogenet Gen 2008;18:317‐23. [PubMed] [Google Scholar]

83. Lanning RK, Zai CC, Muller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics 2016;17:1339‐51. [PubMed] [Google Scholar]

84. Son WY, Lee HJ, Yoon HK et al. GABA transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nordic J Psychiatry 2014;68:123‐8. [PubMed] [Google Scholar]

85. Carbon M, Hsieh CH, Kane JM et al. Tardive dyskinesia prevalence in the period of second‐generation antipsychotic use: a meta‐analysis. J Clin Psychiatry 2017;78:e264‐78. [PubMed] [Google Scholar]

86. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151‐6. [PubMed] [Google Scholar]

87. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. Am J Psychiatry 2004;161:414‐25. [PubMed] [Google Scholar]

88. O'Brien A. Comparing the risk of tardive dyskinesia in older adults with first‐generation and second‐generation antipsychotics: a systematic review and meta‐analysis. Int J Geriatr Psychiatry 2016;31:683‐93. [PubMed] [Google Scholar]

89. Bai YM, Yu SC, Chen JY et al. Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. Int Clin Psychopharmacol 2005;20:79‐85. [PubMed] [Google Scholar]

90. Chan HY, Chiang SC, Chang CJ et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. J Clin Psychiatry 2010;71:1226‐33. [PubMed] [Google Scholar]

91. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15:36S‐44S. [PubMed] [Google Scholar]

92. Bergman H, Walker DM, Nikolakopoulou A et al. Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technol Assess 2017;21:1‐218. [PMC free article] [PubMed] [Google Scholar]

93. Hauser RA, Factor SA, Marder SR et al. KINECT 3: a phase 3 randomized, double‐blind, placebo‐controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174:476‐84. [PubMed] [Google Scholar]

94. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011;45:525‐31. [PubMed] [Google Scholar]

95. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279‐81. [PubMed] [Google Scholar]

96. Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract (in press). [PubMed] [Google Scholar]

97. Fernandez HH, Factor SA, Hauser RA et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM‐TD study. Neurology 2017;88:2003‐10. [PMC free article] [PubMed] [Google Scholar]

98. Alabed S, Latifeh Y, Mohammad HA et al. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203. [PubMed] [Google Scholar]

99. Thaker GK, Nguyen JA, Strauss ME et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445‐51. [PubMed] [Google Scholar]

100. Zhang WF, Tan YL, Zhang XY et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. J Clin Psychiatry 2011;72:615‐21. [PubMed] [Google Scholar]

101. Zhang XY, Zhang WF, Zhou DF et al. Brain‐derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72:700‐6. [PubMed] [Google Scholar]

102. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501. [PubMed] [Google Scholar]

103. Soares‐Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2:CD000209. [PubMed] [Google Scholar]

104. Bhidayasiri R, Fahn S, Weiner WJ et al. Evidence‐based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81:463‐9. [PubMed] [Google Scholar]

105. El‐Sayeh HG, Lyra da Silva JP, Rathbone J et al. Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458. [PubMed] [Google Scholar]

106. Essali A, Deirawan H, Soares‐Weiser K et al. Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206. [PubMed] [Google Scholar]

107. Pouclet‐Courtemanche H, Rouaud T, Thobois S et al. Long‐term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016;86:651‐9. [PubMed] [Google Scholar]

108. Saleh C, Gonzalez V, Coubes P. Role of deep brain stimulation in the treatment of secondary dystonia‐dyskinesia syndromes. Handb Clin Neurol 2013;116:189‐208. [PubMed] [Google Scholar]

109. Sobstyl M, Zabek M. Deep brain stimulation for intractable tardive dystonia: literature overview. Neurol Neurochir Pol 2016;50:114‐22. [PubMed] [Google Scholar]

110. Thobois S, Poisson A, Damier P. Surgery for tardive dyskinesia. Int Rev Neurobiol 2011;98:289‐96. [PubMed] [Google Scholar]

111. Maher S, Cunningham A, O'Callaghan N et al. Clozapine‐induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 2016;6:178‐84. [PMC free article] [PubMed] [Google Scholar]

112. Corrigan FM, MacDonald S, Reynolds GP. Clozapine‐induced hypersalivation and the alpha 2 adrenoceptor. Br J Psychiatry 1995;167:412. [PubMed] [Google Scholar]

113. Ukai Y, Taniguchi N, Ishima T et al. Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and diisopropylfluorophosphate in rat submaxillary glands. Arch Int Pharmacodyn Ther 1989;297:148‐57. [PubMed] [Google Scholar]

114. Saenger RC, Finch TH, Francois D. Aspiration pneumonia due to clozapine‐induced sialorrhea. Clin Schizophr Relat Psychoses 2016;9:170‐2. [PubMed] [Google Scholar]

115. Trigoboff E, Grace J, Szymanski H et al. Sialorrhea and aspiration pneumonia: a case study. Innov Clin Neurosci 2013;10:20‐7. [PMC free article] [PubMed] [Google Scholar]

116. Acosta‐Armas AJ. Two cases of parotid gland swelling in patients taking clozapine. Hosp Med 2001;62:704‐5. [PubMed] [Google Scholar]

117. Patkar AA, Alexander RC. Parotid gland swelling with clozapine. J Clin Psychiatry 1996;57:488. [PubMed] [Google Scholar]

118. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine‐induced sialorrhea. Ann Pharmacother 2011;45:667‐75. [PubMed] [Google Scholar]

119. Essali A, Rihawi A, Altujjar M et al. Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia. Cochrane Database Syst Rev 2013;12:CD009546. [PubMed] [Google Scholar]

120. Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 1999;24:250. [PMC free article] [PubMed] [Google Scholar]

121. Sharma A, Ramaswamy S, Dahl E et al. Intraoral application of atropine sulfate ophthalmic solution for clozapine‐induced sialorrhea. Ann Pharmacother 2004;38:1538. [PubMed] [Google Scholar]

122. Tessier P, Antonello C. Clozapine and sialorrhea: update. J Psychiatry Neurosci 2001;26:253. [PMC free article] [PubMed] [Google Scholar]

123. Calderon J, Rubin E, Sobota WL. Potential use of ipratropium bromide for the treatment of clozapine‐induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 2000;15:49‐52. [PubMed] [Google Scholar]

124. Freudenreich O, Beebe M, Goff DC. Clozapine‐induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 2004;24:98‐100. [PubMed] [Google Scholar]

125. Sockalingam S, Shammi C, Remington G. Treatment of clozapine‐induced hypersalivation with ipratropium bromide: a randomized, double‐blind, placebo‐controlled crossover study. J Clin Psychiatry 2009;70:1114‐9. [PubMed] [Google Scholar]

126. Reinstein M, Sirotovskaya L, Chasanov M et al. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Invest 1999;17:97‐102. [Google Scholar]

127. Spivak B, Adlersberg S, Rosen L et al. Trihexyphenidyl treatment of clozapine‐induced hypersalivation. Int Clin Psychopharmacol 1997;12:213‐5. [PubMed] [Google Scholar]

128. Liang CS, Ho PS, Shen LJ et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine‐induced sialorrhea in schizophrenic patients: a randomized, double‐blind, crossover study. Schizophr Res 2010;119:138‐44. [PubMed] [Google Scholar]

129. Bai YM, Lin CC, Chen JY et al. Therapeutic effect of pirenzepine for clozapine‐induced hypersalivation: a randomized, double‐blind, placebo‐controlled, cross‐over study. J Clin Psychopharmacol 2001;21:608‐11. [PubMed] [Google Scholar]

130. Schneider B, Weigmann H, Hiemke C et al. Reduction of clozapine‐induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004;37:43‐5. [PubMed] [Google Scholar]

131. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine‐induced sialorrhoea. Br J Psychiatry 1991;159:166. [PubMed] [Google Scholar]

132. Grabowski J. Clonidine treatment of clozapine‐induced hypersalivation. J Clin Psychopharmacol 1992;12:69‐70. [PubMed] [Google Scholar]

133. Praharaj SK, Verma P, Roy D et al. Is clonidine useful for treatment of clozapine‐induced sialorrhea? J Psychopharmacol 2005;19:426‐8. [PubMed] [Google Scholar]

134. Webber MA, Szwast SJ, Steadman TM et al. Guanfacine treatment of clozapine‐induced sialorrhea. J Clin Psychopharmacol 2004;24:675‐6. [PubMed] [Google Scholar]

135. Kreinin A, Epshtein S, Sheinkman A et al. Sulpiride addition for the treatment of clozapine‐induced hypersalivation: preliminary study. Isr J Psychiatry Relat Sci 2005;42:61‐3. [PubMed] [Google Scholar]

136. Kreinin A, Miodownik C, Sokolik S et al. Amisulpride versus moclobemide in treatment of clozapine‐induced hypersalivation. World J Biol Psychiatry 2011;12:620‐6. [PubMed] [Google Scholar]

137. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine‐induced hypersalivation in schizophrenia patients: a randomized, double‐blind, placebo‐controlled cross‐over study. Int Clin Psychopharmacol 2006;21:99‐103. [PubMed] [Google Scholar]

138. Kreinin A, Miodownik C, Libov I et al. Moclobemide treatment of clozapine‐induced hypersalivation: pilot open study. Clin Neuropharmacol 2009;32:151‐3. [PubMed] [Google Scholar]

139. Kahl KG, Hagenah J, Zapf S et al. Botulinum toxin as an effective treatment of clozapine‐induced hypersalivation. Psychopharmacology 2004;173:229‐30. [PubMed] [Google Scholar]

140. Steinlechner S, Klein C, Moser A et al. Botulinum toxin B as an effective and safe treatment for neuroleptic‐induced sialorrhea. Psychopharmacology 2010;207:593‐7. [PubMed] [Google Scholar]

141. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple‐treatments meta‐analysis. Lancet 2013;382:951‐62. [PubMed] [Google Scholar]

142. Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012;66:541‐52. [PubMed] [Google Scholar]

143. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl. 2):3‐7. [PMC free article] [PubMed] [Google Scholar]

144. Andrade C, Kisely S, Monteiro I et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta‐analysis of randomized controlled trials. J Psychiatr Res 2015;60:14‐21. [PubMed] [Google Scholar]

145. Burke M, Sebastian CS. Treatment of clozapine sedation. Am J Psychiatry 1993;150:1900‐1. [PubMed] [Google Scholar]

146. Carpenter MD, Winsberg BG, Camus LA. Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol 1992;12:273‐5. [PubMed] [Google Scholar]

147. Szeszko PR, Bilder RM, Dunlop JA et al. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first‐episode schizophrenia at acute and stabilized phases. Biol Psychiatry 1999;45:680‐6. [PubMed] [Google Scholar]

148. Makela EH, Miller K, Cutlip WD 2nd. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 2003;64:485‐6. [PubMed] [Google Scholar]

149. Saavedra‐Velez C, Yusim A, Anbarasan D et al. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009;70:104‐12. [PubMed] [Google Scholar]

150. Freudenreich O, Henderson DC, Macklin EA et al. Modafinil for clozapine‐treated schizophrenia patients: a double‐blind, placebo‐controlled pilot trial. J Clin Psychiatry 2009;70:1674‐80. [PMC free article] [PubMed] [Google Scholar]

151. Miller SC. Methylphenidate for clozapine sedation. Am J Psychiatry 1996;153:1231‐2. [PubMed] [Google Scholar]

152. Saraf G, Viswanath B, Narayanaswamy JC et al. Modafinil for the treatment of antipsychotic‐induced excessive daytime sedation: does it exacerbate tics? J Neuropsychiatry Clin Neurosci 2013;25:E35‐6. [PubMed] [Google Scholar]

153. Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences. Clin Psychopharmacol Neurosci 2016;14:238‐49. [PMC free article] [PubMed] [Google Scholar]

154. Kollin E, Gergely I, Szucs J et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1981;304:1362‐3. [PubMed] [Google Scholar]

155. Gonzalez‐Blanco L, Greenhalgh AM, Garcia‐Rizo C et al. Prolactin concentrations in antipsychotic‐naive patients with schizophrenia and related disorders: a meta‐analysis. Schizophr Res 2016;174:156‐60. [PubMed] [Google Scholar]

156. La Torre A, Conca A, Duffy D et al. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013;46:201‐8. [PubMed] [Google Scholar]

157. de Boer MK, Castelein S, Bous J et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013;150:410‐5. [PubMed] [Google Scholar]

158. Compton MT, Miller AH. Antipsychotic‐induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143‐64. [PubMed] [Google Scholar]

159. Serretti A, Chiesa A. A meta‐analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26:130‐40. [PubMed] [Google Scholar]

160. Berner MM, Hagen M, Kriston L. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2007;1:CD003546. [PubMed] [Google Scholar]

161. Renn JH, Yang NP, Chueh CM et al. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 2009;10:1. [PMC free article] [PubMed] [Google Scholar]

162. Stubbs B, De Hert M, Sepehry AA et al. A meta‐analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 2014;130:470‐86. [PubMed] [Google Scholar]

163. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129‐34. [PubMed] [Google Scholar]

164. Lin CH, Lin CY, Huang TL et al. Sex‐specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol 2015;30:96‐102. [PubMed] [Google Scholar]

165. Catala‐Lopez F, Suarez‐Pinilla M, Suarez‐Pinilla P et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta‐analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom 2014;83:89‐105. [PubMed] [Google Scholar]

166. De Hert M, Peuskens J, Sabbe T et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 2016;133:5‐22. [PubMed] [Google Scholar]

167. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol 2011;74:141‐7. [PubMed] [Google Scholar]

168. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1‐56. [PubMed] [Google Scholar]

169. Peveler RC, Branford D, Citrome L et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22:98‐103. [PubMed] [Google Scholar]

170. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age‐related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003;14:843‐7. [PubMed] [Google Scholar]

171. Tworoger SS, Eliassen AH, Sluss P et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25:1482‐8. [PubMed] [Google Scholar]

172. Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double‐blind, placebo‐controlled, 16‐week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348‐57. [PubMed] [Google Scholar]

173. Chang SC, Chen CH, Lu ML. Cabergoline‐induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008;30:378‐80. [PubMed] [Google Scholar]

174. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic‐induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006;124:291‐7. [PubMed] [Google Scholar]

175. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs 2011;25:659‐71. [PubMed] [Google Scholar]

176. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Safety 2007;16:882‐90. [PubMed] [Google Scholar]

177. Stroup TS, Lieberman JA, McEvoy JP et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107:1‐12. [PMC free article] [PubMed] [Google Scholar]

178. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second‐generation antipsychotic. Int J Clin Pract 2009;63:1237‐48. [PubMed] [Google Scholar]

179. Leung JY, Barr AM, Procyshyn RM et al. Cardiovascular side‐effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012;135:113‐22. [PubMed] [Google Scholar]

180. Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Autonom Res 2008;18(Suppl. 1):14‐8. [PubMed] [Google Scholar]

181. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med 2010;77:298‐306. [PMC free article] [PubMed] [Google Scholar]

182. Testani M Jr. Clozapine‐induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994;55:497‐8. [PubMed] [Google Scholar]

183. Kurihara J, Takata Y, Suzuki S et al. Effect of midodrine on chlorpromazine‐induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. Biol Pharmaceut Bull 2000;23:1445‐9. [PubMed] [Google Scholar]

184. Castrioto A, Tambasco N, Rossi A et al. Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008;255:767‐8. [PubMed] [Google Scholar]

185. Takahashi H. Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia. J Neuropsychiatry Clin Neurosci 2000;12:285‐6. [PubMed] [Google Scholar]

186. Hou PY, Hung GC, Jhong JR et al. Risk factors for sudden cardiac death among patients with schizophrenia. Schizophr Res 2015;168:395‐401. [PubMed] [Google Scholar]

187. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225‐35. [PMC free article] [PubMed] [Google Scholar]

188. Straus SM, Bleumink GS, Dieleman JP et al. Antipsychotics and the risk of sudden cardiac death. Arch Int Med 2004;164:1293‐7. [PubMed] [Google Scholar]

189. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation‐wide case‐crossover study. J Am Heart Assoc 2015;4:e001568. [PMC free article] [PubMed] [Google Scholar]

190. Mehtonen OP, Aranko K, Malkonen L et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58‐64. [PubMed] [Google Scholar]

191. Reilly JG, Ayis SA, Ferrier IN et al. Thioridazine and sudden unexplained death in psychiatric in‐patients. Br J Psychiatry 2002;180:515‐22. [PubMed] [Google Scholar]

192. Ray WA, Meredith S, Thapa PB et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161‐7. [PubMed] [Google Scholar]

193. Haddad PM, Anderson IM. Antipsychotic‐related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649‐71. [PubMed] [Google Scholar]

194. Heist EK, Ruskin JN. Drug‐induced proarrhythmia and use of QTc‐prolonging agents: clues for clinicians. Heart Rhythm 2005;2:S1‐8. [PubMed] [Google Scholar]

195. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death – how should we manage the risk? N Engl J Med 2009;360:294‐6. [PubMed] [Google Scholar]

196. Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014;20:196‐206. [PubMed] [Google Scholar]

197. Lieberman JA, Merrill D, Parameswaran S. APA guidance on the use of antipsychotic drugs and cardiac sudden death. //www.omh.ny.gov.

198. Kavanaugh G, Brown G, Khan I et al. Guidance on the use of antipsychotics, Version 3.2. London: National Health Service, 2015. [Google Scholar]

199. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016;50:973‐81. [PubMed] [Google Scholar]

200. Trollor JN, Chen X, Chitty K et al. Comparison of neuroleptic malignant syndrome induced by first‐ and second‐generation antipsychotics. Br J Psychiatry 2012;201:52‐6. [PubMed] [Google Scholar]

201. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477‐92. [PubMed] [Google Scholar]

202. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome – an 11‐year longitudinal case‐control study. Can J Psychiatry 2012;57:512‐8. [PubMed] [Google Scholar]

203. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870‐6. [PubMed] [Google Scholar]

204. Su YP, Chang CK, Hayes RD et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014;130:52‐60. [PubMed] [Google Scholar]

205. Tse L, Barr AM, Scarapicchia V et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 2015;13:395‐406. [PMC free article] [PubMed] [Google Scholar]

206. Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499‐507. [PubMed] [Google Scholar]

207. Patil BS, Subramanyam AA, Singh SL et al. Low serum iron as a possible risk factor for neuroleptic malignant syndrome. Int J Appl Basic Med Res 2014;4:117‐8. [PMC free article] [PubMed] [Google Scholar]

208. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149‐51. [PubMed] [Google Scholar]

209. Patel AL, Shaikh WA, Khobragade AK et al. Electroconvulsive therapy in drug resistant neuroleptic malignant syndrome. J Assoc Physicians India 2008;56:49‐50. [PubMed] [Google Scholar]

210. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185‐202. [PubMed] [Google Scholar]

211. Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 1988;22:475‐80. [PubMed] [Google Scholar]

212. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50:295‐8. [PubMed] [Google Scholar]

213. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999;33:650‐9. [PubMed] [Google Scholar]

214. Idänpään‐Heikkilä J, Alhava E, Olkinuora M et al. Clozapine and agranulocytosis. Lancet 1975;306:611. [PubMed] [Google Scholar]

215. Alvir JM, Lieberman JA, Safferman AZ et al. Clozapine‐induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162‐7. [PubMed] [Google Scholar]

216. Canoso RT, Lewis ME, Yunis EJ. Association of HLA‐Bw44 with chlorpromazine‐induced autoantibodies. Clin Immunol Immunopathol 1982;25:278‐82. [PubMed] [Google Scholar]

217. Fiore JM, Francis MN. Agranulocytosis due to mepazine (phenothiazine): report of three cases. N Engl J Med 1959;260:375‐8. [PubMed] [Google Scholar]

218. Goldman D. Agranulocytosis associated with administration of chlorpromazine: report of three cases with description of treatment and recovery. AMA Arch Int Med 1955;96:496. [PubMed] [Google Scholar]

219. Stergiou V, Bozikas VP, Garyfallos G et al. Olanzapine‐induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:992‐4. [PubMed] [Google Scholar]

220. Sluys M, Güzelcan Y, Casteelen G et al. Risperidone‐induced leucopenia and neutropenia: a case report. Eur Psychiatry 2004;19:117. [PubMed] [Google Scholar]

221. Munro J, O'Sullivan D, Andrews C et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576‐80. [PubMed] [Google Scholar]

222. Sporn A, Gogtay N, Ortiz‐Aguayo R et al. Clozapine‐induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13:401‐4. [PubMed] [Google Scholar]

223. Papetti F, Darcourt G, Giordana J‐Y et al. Treatment of clozapine‐induced granulocytopenia with lithium (two observations). Encéphale 2004;30:578‐82. [PubMed] [Google Scholar]

224. Yadav D, Burton S, Sehgal C. Clozapine‐induced neutropenia reversed by lithium. Prog Neurol Psychiatry 2016;20:13‐5. [Google Scholar]

225. Nielsen H. Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF; filgrastim) treatment of clozapine‐induced agranulocytosis. J Int Med 1993;234:529‐31. [PubMed] [Google Scholar]

226. Lamberti JS, Bellnier TJ, Schwarzkopf SB et al. Filgrastim treatment of three patients with clozapine‐induced agranulocytosis. J Clin Psychiatry 1995;56:256‐9. [PubMed] [Google Scholar]

227. Simon L, Cazard F. Clozapine rechallenge after neutropenia in resistant schizophrenia: a review. Encéphale 2016;42:346‐53. [PubMed] [Google Scholar]

228. Gaboriau L, Victorri‐Vigneau C, Gérardin M et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav 2014;39:562‐5. [PubMed] [Google Scholar]

229. Smith N, Kitchenham N, Bowden‐Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry 2011;199:158‐9. [PubMed] [Google Scholar]

230. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524‐9. [PubMed] [Google Scholar]

231. Claassen DO, van den Wildenberg WP, Ridderinkhof KR et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci 2011;125:492‐500. [PMC free article] [PubMed] [Google Scholar]

232. Etminan M, Sodhi M, Samii A et al. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic study. J Clin Psychopharmacol 2017;37:102‐4. [PubMed] [Google Scholar]

233. Cheon E, Koo BH, Seo SS et al. Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Invest 2013;10:200‐2. [PMC free article] [PubMed] [Google Scholar]

234. Cohen J, Magalon D, Boyer L et al. Aripiprazole‐induced pathological gambling: a report of 3 cases. Curr Drug Saf 2011;6:51‐3. [PubMed] [Google Scholar]

235. Haas SJ, Hill R, Krum H et al. Clozapine‐associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993‐2003. Drug Saf 2007;30:47‐57. [PubMed] [Google Scholar]

236. Ronaldson K, Fitzgerald P, Taylor A et al. Clinical course and analysis of ten fatal cases of clozapine‐induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011;128:161‐5. [PubMed] [Google Scholar]

237. Chopra N, de Leon J. Clozapine‐induced myocarditis may be associated with rapid titration: a case report verified with autopsy. Int J Psychiatry Med 2016;51:104‐15. [PubMed] [Google Scholar]

238. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine‐induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas Psychiatry 2016;24:176‐80. [PubMed] [Google Scholar]

239. Freudenreich O. Clozapine‐induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015;132:240‐1. [PubMed] [Google Scholar]

240. Ellis PM, Cameron CR. Clozapine‐induced myocarditis and baseline echocardiograms. Aust N Z J Psychiatry 2012;46:1005‐6. [PubMed] [Google Scholar]

241. Ittasakul P, Archer A, Kezman J et al. Rapid re‐challenge with clozapine following pronounced myocarditis in a treatment‐resistance schizophrenia patient. Clin Schizophr Relat Psychoses 2013;10:120‐2. [PubMed] [Google Scholar]

242. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 2007;68(Suppl. 4):19‐25. [PubMed] [Google Scholar]

243. Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight‐loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594‐602. [PMC free article] [PubMed] [Google Scholar]

244. Bartels SJ, Pratt SI, Aschbrenner KA et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 2015;172:344‐52. [PMC free article] [PubMed] [Google Scholar]

245. Green CA, Yarborough BJ, Leo MC et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015;172:71‐81. [PMC free article] [PubMed] [Google Scholar]

246. Wu RR, Zhao JP, Guo XF et al. Metformin addition attenuates olanzapine‐induced weight gain in drug‐naive first‐episode schizophrenia patients: a double‐blind, placebo‐controlled study. Am J Psychiatry 2008;165:352‐8. [PubMed] [Google Scholar]

247. Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic induced weight gain: a randomized controlled trial. JAMA 2008;299:185‐93. [PubMed] [Google Scholar]

248. Jarskog LF, Hamer RM, Catellier DJ et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013;170:1032‐40. [PMC free article] [PubMed] [Google Scholar]

249. Baptista T, Rangel N, Fernández V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double‐blind, placebo‐controlled trial. Schizophr Res 2007;93:99‐108. [PubMed] [Google Scholar]

250. Tek C, Ratliff J, Reutenauer E et al. A randomized, double‐blind, placebo‐controlled pilot study of naltrexone to counteract antipsychotic‐associated weight gain: proof of concept. J Clin Psychopharmacol 2014;34:608‐12. [PMC free article] [PubMed] [Google Scholar]

251. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004;6(Suppl. 2):20‐3. [PMC free article] [PubMed] [Google Scholar]

252. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012;38:592‐8. [PMC free article] [PubMed] [Google Scholar]

253. Every‐Palmer S, Ellis PM. Clozapine‐induced gastrointestinal hypomotility: a 22‐year bi‐national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs 2017;31:699‐709. [PMC free article] [PubMed] [Google Scholar]

254. Hayat U, Dugum M, Garg S. Chronic constipation: update on management. Cleve Clin J Med 2017;84:397‐408. [PubMed] [Google Scholar]

255. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209‐23. [PubMed] [Google Scholar]

Page 2

Side effect profiles of selected antipsychotic drugs